An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

被引：50

作者：

Schey, SA ^{[1
]}

Cavenagh, J

Johnson, R

Child, JA

Oakervee, H

Jones, RW

机构：

[1] Univ London, Dept Hematol, Guys Hosp, Kings Coll London Med Sch, London SE1 9RT, England

[2] Barts & Royal London Hosp, Dept Haematol, London, England

[3] Birmingham Heartlands NHS Trust, Dept Haematol, Birmingham, W Midlands, England

[4] Gen Infirm, Dept Haematol, Leeds LS1 3EX, W Yorkshire, England

来源：

LEUKEMIA RESEARCH | 2003年 / 27卷 / 10期

关键词：

multiple myeloma; relapsed disease; thalidomide; treatment recommendations;

D O I：

10.1016/S0145-2126(03)00027-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myeloma remains incurable with conventional treatment in the vast majority of patients. The introduction of thalidomide in 1999 for the treatment of relapsed disease offers the opportunity to treat patients who have developed myelotoxicity or who are refractory to conventional chemotherapy. The optimal schedule remains unresolved and only two studies have reported long term follow-up data. We report a phase 11 low dose escalation study of thalidomide with long term follow-up showing overall survival (OS) of 19 months and progression free survival (PFS) of 14 months. In addition we report on the side effects and toxicity and give recommendations for the use of thalidomide in the relapsed setting based upon these findings. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：909 / 914

页数：6

共 27 条

[1]

ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8

[2] Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies [J].

Bellamy, WT .

SEMINARS IN ONCOLOGY, 2001, 28 (06) :551-559

[3] Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation [J].

Bjorkstrand, B ;

Ljungman, P ;

Svensson, H ;

Hermans, J ;

Alegre, A ;

Apperley, J ;

Blade, J ;

Carlson, K ;

Cavo, M ;

Ferrant, A ;

Goldstone, AH ;

deLaurenzi, A ;

Majolino, I ;

Marcus, R ;

Prentice, HG ;

Remes, K ;

Samson, D ;

Sureda, A ;

Verdonck, LF ;

Volin, L ;

Gahrton, G .

BLOOD, 1996, 88 (12) :4711-4718

[4] European group for blood and marrow transplantation registry studies in multiple myeloma [J].

Björkstrand, B .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :219-225

[5]

BUCAID AC, 1964, JAMA-J AM MED ASSOC, V189, P758

[6] Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy [J].

Cavo, M ;

Zamagni, E ;

Cellini, C ;

Tosi, P ;

Cangini, D ;

Cini, M ;

Valdrè, L ;

Palareti, G ;

Masini, L ;

Tura, S ;

Baccarani, M .

BLOOD, 2002, 100 (06) :2272-2273

[7] Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B [J].

Chauhan, D ;

Uchiyama, H ;

Akbarali, Y ;

Urashima, M ;

Yamamoto, K ;

Libermann, TA ;

Anderson, KC .

BLOOD, 1996, 87 (03) :1104-1112

[8]

Corral LG, 1999, J IMMUNOL, V163, P380

[9] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[10]

DAMIANO JS, 1999, CELL ADHESION MEDIAT

← 1 2 3 →